Adenocarcinoma of the lacrimal glands

Last revised by Ammar Haouimi on 23 Oct 2020

Adenocarcinoma of the lacrimal glands is rare, with few cases reported in the literature since it was first described in 1996 1. Primary adenocarcinoma of the lacrimal gland is extremely rare; only 9 cases have been reported in the literature 1,2. It can be classified into high- and low-grade malignancies. This neoplasm is histologically and immunohistochemically similar to salivary ductal carcinoma 3.

They usually present as unilateral gland enlargement with displacement of the eye.

Histologic examination shows a well-circumscribed but unencapsulated neoplasm. The cells are highlighted by the calponin immunostain, consistent with myoepithelial differentiation. These cells have round to oval nuclei with a uniform vesicular chromatin pattern and small nucleoli. Most of these cells exhibit cytoplasmic and membranous staining for C-kit (CD117). p53 expression is seen in a minority of the nuclei. A significant number of luminal structures contain mucicarmine-positive material. The tumor cells are uniformly negative for GFAP.

A rounded extraconal mass centered around the lacrimal gland in the superolateral aspect of the orbit.

Axial and coronal CT shows peripheral and mild central heterogeneous enhancement.

Signal characteristics include:

  • T1: intermediate intensity lacrimal fossa mass
  • T2: usually hyperintense
  • T1 C+: heterogeneous enhancement
  • DWI and ADC: diffusion restriction of the peripherally enhancing component

The tumor is usually treated with complete excision, lymph node dissection, and adjuvant radiotherapy. Because there are few reports of this entity, its clinical behavior, prognosis and definitive treatment are still unknown 2,4.

Possible differential considerations include:

ADVERTISEMENT: Supporters see fewer/no ads

Updating… Please wait.

 Unable to process the form. Check for errors and try again.

 Thank you for updating your details.